Table 2 Differences in clinical characteristics in subjects with T2D after twelve-months of IMT

Fasting glucose (mg/dl)

13

180.0 [161.0,240.0]

13

108.0 [88.0,128.0]

13

−87.0 [−127.0,−41.0]

0.002

HGBA1C (%)

13

9.1 [8.9,10.2]

13

6.1 [6.0,6.7]

13

−3.0 [−4.1,−2.1]

< 0.001

Body weight (kg)

13

96.8 [93.2,111.1]

13

83.5 [69.4,92.1]

13

−14.7 [−37.9,−5.9]

< 0.001

BMI (kg/m²)

13

36.5 [33.4,37.5]

13

28.0 [26.4,30.7]

13

−5.9 [−9.2,−2.0]

< 0.001

HDL-cholesterol (mg/dl)

13

41.0 [37.0,45.0]

13

50.0 [46.0,56.0]

13

7.0 [4.0,16.0]

< 0.001

Triglycerides (mg/dl)

13

174.0 [152.0,337.0]

13

119.0 [94.0,152.0]

13

−42.0 [−135.0,−13.0]

< 0.001

Tumor necrosis factor

13

1.4 [1.02,2.0]

13

1.04 [0.61,1.1]

13

−0.39 [−0.68,−0.23]

0.006

C-reactive protein (mg/dl)

13

5.5 [3.1,6.2]

13

1.00 [0.50,3.1]

13

−2.5 [−4.5,−1.7]

< 0.001

Adiponectin (ug/ml)

13

2.8 [2.4,4.0]

13

6.1 [4.7,9.2]

13

2.9 [2.2,5.5]

0.001

Leptin (ng/ml)

13

22.7 [15.8,32.4]

13

13.6 [9.3,23.6]

13

−11.5 [−16.6,−2.0]

0.006

Total cholesterol (mg/dl)

13

187.0 [172.0,202.0]

13

182.0 [152.0,209.0]

13

2.0 [−38.0,13.0]

0.53

LDL-cholesterol (mg/dl)

13

104.0 [82.0,114.0]

13

91.0 [73.0,127.0]

13

−2.0 [−18.0,11.0]

0.58

MPO activity (mOD/μL/min)

12

6.5 [5.6,20.9]

12

5.9 [4.9,8.6]

12

−1.3 [−9.0,0.30]

0.18

pHDL assay (RFU mg HDLc/min)

12

0.49 [0.42,0.54]

12

0.43 [0.35,0.51]

12

−0.11 [−0.13,0.01]

0.083

pHDL assay (RFU mg HDLc/min)

11

0.49 [0.42,0.54]

11

0.40 [0.34,0.51]

11

−0.13 [−0.13, −0.02]

0.040 ^a

Cp activity (μmol.min-1/mL)

12

0.16 [0.14,0.17]

12

0.14 [0.13,0.19]

12

0.00 [−0.02,0.02]

0.98

PONI activity (nmole.min-1/μL)

12

0.01 [0.01,0.01]

12

0.02 [0.01,0.03]

12

0.01 [0.00,0.02]

< 0.001

Systolic blood pressure (mmHG)

13

137.0 [133.0,156.0]

13

129.0 [117.0,141.0]

13

−8.0 [−22.0,3.0]

0.051

Diastolic blood pressure (mmHG)

13

89.0 [83.0,91.0]

13

79.0 [72.0,85.0]

13

−8.0 [−11.0,−1.00]

0.005